Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation

International Journal of Radiation Biology

Volumn 87, Issue 11, 2011, Pages 1126-1134

  Bertelsen, Lotte B ^a   Shen, Yuan Yuan ^a,b   Nielsen, Thomas ^a   Stødkilde Jørgensen, Hans ^a   Kenneth Lloyd, G ^c   Siemann, Dietmar W ^d   Horsman, Michael R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BINZHOU MEDICAL UNIVERSITY   (China)

^c Nereus Pharmaceuticals   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

C3H mammary carcinoma; KHT sarcoma; Magnetic resonance imaging; Plinabulin (NPI 2358); Radiation; Vascular targeting

Indexed keywords

GADOLINIUM PENTETATE; PLINABULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER RADIOTHERAPY; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIZATION; SARCOMA; TREATMENT RESPONSE; TUMOR NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMIDAZOLES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; PIPERAZINES; SARCOMA, EXPERIMENTAL;

EID: 80455129668     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2011.605418     Document Type: Article

References (43)

1. Bentzen L, Vestergaard-Poulsen P, Nielsen T, Overgaard J, Bjørnerud A, Briley-SaebøK, Horsman MR, Østergaard L. 2005. Intravascular contrast enhanced MRI measuring contrast clearance and tumour blood volume and the effects of vascular modifiers in an experimental tumour. International Journal of Radiation Oncology Biology Physics 61:1208-1215.
2. Breidahl T, Nielsen FU, Stødkilde-Jørgensen H, Maxwell RJ, Horsman MR. 2006. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS. Acta Oncologica 45:306-316.
3. Brem S, Brem H, Folkman J, Finkelstein D, Patz A. 1976. Prolonged tumor dormancy by prevention of neo-vascularization in the vitreous. Cancer Research 36:2807-2812.
4. Chaplin DJ, Pettit GR, Hill SA. 1999. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Research 19:189-196.
5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. 1997.Combretastatin A-4, an agent that displays potent and selective toxicity towards tumor vasculature. Cancer Research 57:1829-1834.
6. Folkman J. 1986. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Research 46:467-473.
7. Furman-Haran E, Grobgeld D, Degani H. 1997. Dynamic contrastenhanced imaging and analysis at high spatial resolution of MCF7 human breast tumors. Journal of Magnetic Resonance 128:161-171.
8. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. 1999. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. British Journal of Cancer 81:1318-1327.
9. Horsman MR, Finch A, Overgaard J. 2003. Erythropoietin improves the oxygen carrying capacity of mouse blood without changing hypoxia in a murine tumor model. European Journal of Cancer (Suppl. 1):S13.
10. Horsman MR, Hansen PV, Overgaard J. 1989. Radiosensitization by nicotinamide in tumors and normal tissues: The importance of tissue oxygenation status. International Journal of Radiation Oncology Biology Physics 16:1273-1276.
11. Horsman MR, Murata R. 2002. Combination of vascular targeting agents with thermal and radiation therapy. International Journal of Radiation Oncology Biology Physics 54:1518-1523.
12. Horsman MR, Murata R. 2003. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. International Journal of Radiation Oncology Biology Physics 57:1047-1055.
13. Horsman MR, Murata R, Breidahl T, Nielsen FU, Maxwell RJ, Stødkilde-Jørgensen H, Overgaard J. 2000. Combretastatins: Novel vascular targeting drugs for improving anti-cancer therapy. Advances in Experimental Medicine and Biology 476:311-323.
14. Horsman MR, Murata R, Overgaard J. 2002. Combination studies with combretastatin and radiation: Effects in early and late responding tissues. Radiotherapy Oncology 64:S50.
15. Horsman MR, Siemann DW. 2006. Pathophysiological effects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Research 66:11520-11539.
16. Kallman RF, Silini G, Van Putten LM. 1967. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. Journal of the National Cancer Institute 39:539-549.
17. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. 1998. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by the combination with 5-hydroxytryptamine and bioreductive drugs. British Journal of Cancer 78:439-445.
18. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson G, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin G, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P. 2003. Assessment of antiangiogenic and antivascular therapeutics using MRI: Recommendations for appropriate methodology for clinical trials. British Journal of Radiology 76:S87-91.
19. Ley CD, Horsman MR, Kristjansen PEG. 2007. Early effects of combretastatin A-4 phosphate on tumor perfusion and interstitial fluid pressure. Neoplasia 9:108-112.
20. Li L, Rojiani A, Siemann DW. 1998. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy. International Journal of Radiation Oncology Biology Physics 42:899-903.
21. Maxwell RJ, Nielsen FU, Breidahl T, Stødkilde-Jørgensen H, Horsman MR. 1998. Effectsof combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI. International Journal of Radiation Oncology Biology Physics 42:891-894.
22. Mita MM, Spear MA, Yee LK, Mita AC, Heath EI, Papadopoulos KP, Federico KC, Reich SD, Romero O, Malburg L, Pilat MJ, Lloyd GK, Neuteboom STC, Cropp G, Ashton E, LoRusso PM. 2010a. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clinical Cancer Research 16:5892-5899.
23. Mita AC, Heist RS, Aren O, Mainwaring PN, Bazhenova L, Gadgeel SM, Blum RH, PolikoffJ, Biswas J, Spear MA. 2010b. Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 28:7592.
24. Murata R, Siemann DW, Overgaard J, Horsman MR. 2001a. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumours. Radiotherapy and Oncology 60:155-161.
25. Murata R, Siemann DW, Overgaard J, Horsman MR. 2001b. Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiation Research 156:503-509.
26. Murata R, Overgaard J, Horsman MR. 2001c. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. International Journal of Radiation Biology 77:195-204.
27. Nicholson B, Lloyd GK, Miller BR, Palladino MA, Kiso Y, Hayashi Y, Neuteboom STC. 2006. NPI-2358 is a tubulin-depolymerizing agent: In-vitro evidence for activity as a tumor vascular-disrupting agent. Anti-Cancer Drugs 17:25-31.
28. Nielsen T, Murata R, Maxwell RJ, Stødkilde-Jørgensen H, Østergaard L, Horsman MR. 2008. Preclinical studies to predict the efficacy of the vascular changes induced by combretastatin A-4 disodium phosphate in patients. International Journal of Radiation Oncology Biology Physics 70:859-866.
29. Nielsen T, Murata R, Maxwell RJ, Stødkilde-Jørgensen H, Østergaard L, Ley CD, Kristjansen PEG, Horsman MR. 2010. Non-invasive imaging of combretastatin activity in different tumour models: Association with more invasive estimates. Acta Oncologica 49:906-913.
30. Overgaard J. 1980. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. International Journal of Radiation Oncology Biology Physics 6:1507-1517.
31. Patterson DM, Rustin GJS. 2007. Vascular damaging agents. Clinical Oncology 19:443-456.
32. Pedersen M, Mørkenborg J, Jensen FT, Stødkilde- Jørgensen H, Djurhuus JC, Frokiaer J. 2000. In vivo measurements of relaxivities in the rat kidney cortex. Journal of Magnetic Resonance Imaging 12:289-296.
33. Shi W, Siemann DW. 2005. Preclinical studies of the novel vascular targeting agent MN-029. Anticancer Research 25:3899-3904.
34. Siemann DW. 1995. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiotherapy Oncology 34:47-53.
35. Siemann DW. Vascular targeting agents. 2002. Horizons in Cancer Therapeutics 3:4-15.
36. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FALM, Horsman MR, Marmé D, LoRusso PM. 2005. Differentiation and definition of vascular-targeted therapies. Clinical Cancer Research 11:416-420.
37. Siemann DW, Hill RP, Bush RS. 1977. The importance of the preirradiation breathing times of oxygen and carbogen (5% CO 2 :95% O 2 ) on the in vivo radiation response of a murine sarcoma. International Journal of Radiation Oncology Biology Physics 2:903-911.
38. Siemann DW, Rojiani AM. 2002. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. International Journal of Radiation Oncology Biology Physics 53:164-171.
39. Siemann DW, Rojiani AM. 2005. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large advanced tumors. International Journal of Radiation Oncology Biology Physics 62:846-853.
40. Siemann DW, Warrington KH, Horsman MR. 2000. Vascular targeting agents: Adjuvants to radiation therapy. Radiotherapy Oncology 57:5-12.
41. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, WeisskoffRM. 1999. Estimating kinetic parameters from dynamic contrastenhanced T(1)-weighted MRI of a diffusible tracer: Standardized quantities and symbols. Journal of Magnetic Resonance Imaging 10:223-232.
42. Tozer GM, Kanthou C, Baguley BC. 2005. Disrupting tumour blood vessels. Nature Reviews Cancer 5:423-435.
43. Wilson WR, Li AE, Cowan D, Siim BG. 1998. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. International Journal of Radiation Oncology Biology Physics 42:905-908.